Ann: 1st patient dosed in CHM 0201 Vactosertib trial, page-11

Just noticed that the CHM 0201 Vactosertib trial is currently suspended (temporarily) due to insufficient staff (Christmas break?):


https://clinicaltrials.gov/study/NCT05400122?tab=table

Primary Completion Date however remains unchanged (Estimated): 1 June 2024.

Given the time Primary Outcome (1.) being 28 days after infusion, that would indicate dosing of the last patient to occur beginning of May (estimated).

Also worth noting that the trial seeks to enrol "up to 12 patients":
https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.4_suppl.TPS273



https://chimerictherapeutics.com/our-pipeline/#our-pipeline

This trial is not the same as the ADVENT-AML Phase 1B trial:
https://clinicaltrials.gov/study/NCT05834244


https://chimerictherapeutics.com/our-pipeline/#our-pipeline


Both trials are utilising the non-engineered allogeneic CORE-NK platform (CHM 0201), which is different to the autologous therapy CHM 1101 (CLTX), which recently dosed the last patient in a Phase 1A dose escalation study:
https://clinicaltrials.gov/study/NCT04214392


https://www.businessnews.com.au/article/Chimeric-moves-US-brain-cancer-trial-to-next-stage

Positive Preliminary Data was announced in October last year:


https://chimerictherapeutics.com/wp-content/uploads/2023/10/ASX-Announcement-23Oct2023-2627696.pdf

CLTX is currently tested in a Phase 1B trial:
https://clinicaltrials.gov/study/NCT05627323


https://chimerictherapeutics.com/our-pipeline/#clinical-trials

CHM 2101, an autologous CDH17 CAR T-cell therapy is due to start recruitment within the next 6 months in a Phase 1 dose escalation study, with Phase 2 dosing based on results from Phase 1:
https://classic.clinicaltrials.gov/ct2/show/NCT06055439


So much to see here...